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Background: Detection of the human epididymis secretory protein 4 (HE4) biomarker plays 
an important role in the early diagnosis of ovarian cancer. This study aimed to develop a novel 
localized surface plasmon resonance (LSPR) biosensor for detecting HE4 in blood samples 
from patients with ovarian cancer.
Methods: Silver nanoparticles were fabricated using a nanosphere lithography method. The 
anti-HE4 antibody as a probe, which can distinctly recognize HE4, was assembled onto the 
nanochip surface using an amine coupling method. Detection was based on the shift in the 
extinction maximum of the LSPR spectrum before and after the HE4-anti-HE4 antibody reaction. 
These nanobiosensors were applied to detect HE4 in human serum samples and compare them 
using an enzyme-linked immunosorbent assay.
Results: Tests relating to the detection of HE4 demonstrated that the LSPR-based biosensor 
featured a fast detection speed, good specificity, effective reproducibility, and long-term stability. 
The linear range for LSPR was between 10 pM and 10,000 pM, with a detection limit of 4 pM. 
An excellent correlation between LSPR and enzyme-linked immunosorbent assay results was 
observed in human serum.
Conclusion: This study is the first clinical diagnostic application of the LSPR biosensor in 
ovarian cancer. The LSPR biosensor, a rapid, low-cost, label-free and portable screening tool, can 
serve as a very effective alternative for the clinical serological diagnosis of ovarian cancer.
Keywords: localized surface plasmon resonance system, nanobiosensor, ovarian cancer 
biomarker, serum HE4 protein
Introduction
Since the advent of nanotechnology, nanoscale particle-based sensors have attracted 
tremendous attention from scientists, because of their unique optical and electrical 
properties.1–4 Localized surface plasmon resonance (LSPR), which is recognized as 
one of the special optical properties of noble metallic nanoparticles (eg, silver or 
gold), is generated when the incident photon frequency is resonant with the collective 
oscillation of conduction electrons.5 The LSPR biosensor, a novel type of optical fiber-
based biosensor, uses an optical fiber or optical fiber bundle to transform biological 
recognition information into analytically useful signals in the LSPR spectrum, and has 
been proven to be an effective platform for detection techniques.5,6 The sensing principle 
is based on its sensitivity to local refractive index changes near the nanoparticle surface 
induced by biomolecular interactions.5–8 The applicability of this nanobiosensor has 
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been studied in many fields, such as drug screening, medical 
diagnostics, and environmental monitoring, and has become 
a hot research topic all over the world.9–13
The detection of biotin-streptavidin and microalbumin 
in patients’ urine using the proposed domestic LSPR 
  biosensor has been reported previously, without quantitative 
analysis.14,15 However, to date, this biosensor has not been 
widely utilized in the field of gynecological oncology.
Ovarian cancer is one of the most common malignancies 
of the female reproductive system. According to the 
  American Cancer Society, ovarian cancer accounts for about 
4% of cancers occurring in women, but ranks fourth among 
the cancer-related deaths in women, because most cases are 
unfortunately diagnosed at an advanced stage.16 Currently, 
CA125 is the only biomarker of ovarian cancer that is most 
widely and routinely used in clinical practice. However, 
the clinical use of CA125 as a marker for early detection 
is severely restricted, because it is elevated in only half of 
early-stage ovarian cancers and is elevated frequently in 
many benign gynecological diseases, such as endometriosis, 
ovarian cysts, and pelvic inflammation.17,18 Recently, the 
human epididymis secretory protein 4 (HE4), which is a novel 
biomarker for ovarian cancer, has been widely studied and 
used in the early diagnosis of ovarian cancer. Reportedly, 
HE4 is highly sensitive to early ovarian cancer and can be 
used in combination with CA125, offering the best method 
of differential diagnosis in ovarian cancer and other pelvic 
masses.19–21
Currently used approaches for detection of HE4 are 
the enzyme-linked immunosorbent assay (ELISA) and 
the chemiluminescent immunoassay (CLIA). Although it 
is one of the most mature methods for protein detection 
used in the last three decades and is considered the gold 
standard, ELISA still has certain shortcomings in terms 
of the long assay time required, the indirect detection 
format, and the need for multiple washing steps.22 
CLIA also has some disadvantages, including the large 
volume of the analysis instrument, high cost, and special 
labeling requirements. These factors constrain the clinical 
application of these techniques. Thus, a rapid, label-free, 
simple, low-cost, and portable protocol for detecting HE4 
is urgently required.
In the present work, the LSPR biosensor developed 
was utilized based on silver nanoparticles for the direct 
detection of the HE4 biomarker in blood samples 
from patients with ovarian cancer. Under the optimum 
conditions, HE4 in both buffer and human serum samples 
are tested. The results are then compared using ELISA. 
Based on current information, this study is the first to 
investigate the LSPR system for the detection of HE4. 
The study is also the first to discuss and analyze in detail 
the detection limit, linear range, and regeneration of the 
proposed homemade LSPR sensor.
Materials and methods
Materials
11-Mercaptoundecanoic acid and bovine serum albumin 
were purchased from Sigma-Aldrich (St Louis, MO). 
N-hydroxysuccinimide and 1-ethyl-3-(3-  dimethylamino  propyl) 
carbodiimide hydrochloride (EDC) were purchased from 
Aladdin (Shanghai, China). Mouse monoclonal anti-HE4 
antibody (anti-HE4) and standard HE4 were obtained from 
Abnova (Taiwan, China). Ethanolamine was purchased from 
the Kelang Company (Chengdu, China). An HE4 ELISA kit 
was obtained from Fujirebio Diagnostics Inc (Malvern, PA). 
Ultrapure water (18.3 MΩ/cm) used for the preparation of all 
solutions was obtained from Millipore Co (Boston, MA). All 
reagents used were of analytical reagent grade.
Patients and samples
The human serum specimens were collected from West 
China Second University Hospital (Chengdu, China). Written 
informed consents were not obtained, because these samples 
were from leftover blood samples in routine blood tests, and 
this study did not cause any harm to the patients. Sera were 
isolated through the centrifugation of whole blood samples 
at 2000 rpm for 20 minutes, and subsequently kept frozen 
at −80°C until analysis.
Preparation of LSPR biosensor  
and experimental setup
The integrated LSPR biosensor used in this work was a 
custom system built on-site, as previously described in 
detail.14,23 The silver nanochip was fabricated using the 
nanosphere lithography method. The peak wavelength 
of the LSPR extinction spectrum (λmax) excited by the 
silver nanoparticles was measured and recorded using 
an ultraviolet-visible spectroscope (Sciencetech 9055, 
Sciencetech, Ottawa, Canada) with a charge-coupled device 
detector (Koan Electro-Optics Co, Shanghai, China).14
The entire measurement process could be described as 
follows. The white light emerging from an optical fiber 
bundle and the transmitted light coupled into the detection 
probe of the optical fiber bundle provided the incident light. 
The nanochip was placed perpendicular to the incident light, 
which was taken using the ultraviolet-visible spectrometer 
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ranging from 400 nm to 800 nm at room temperature in 
air.14 All the extinction spectra could be calculated through a 
software program (Ocean Optics, Dunedin, FL) and directly 
displayed on the screen of the computer. Thus, the data of 
different nanochips could be compared. The shift toward 
longer wavelengths, defined as a red shift, was indicated as 
(+), whereas the shift toward shorter wavelengths, defined 
as a blue shift, was indicated as (−). The relative wavelength 
shift, namely ∆λmax, was used to monitor the binding of 
target analytes.13 The experimental setup is illustrated in 
Figure 1.
Functionalization of LSPR biosensor
Functionalization is a multistep process that prepares the LSPR 
nanosensor for biodetection events (Figure 2). First, the silver 
nanochip was incubated in 1 mM 11-mercaptoundecanoic 
acid solution (in ethanol) for 12 hours to form a self-
assembled monolayer on the slice surface, after which the 
nanochip was washed thoroughly with ethanol and dried 
at room temperature. The nanochip was then immersed in 
75 mM EDC/15 mM N-hydroxysuccinimide solution for 
2 hours to activate the carboxyl groups of the self-assembled 
monolayer, which reacts with amino groups of antibodies 
to form amides. Subsequently, 50 µL of anti-HE4 solution 
at 10 µg/mL was spotted on the self-assembled monolayer-
modified surface and overnight incubation at 4°C followed. 
The anti-HE4 immobilized surface was immersed in 1 M 
ethanolamine solution (pH 8.5) for 30 minutes to deactivate 
the unreacted esters, after which the surface was washed with 
phosphate-buffered solution (pH 7.4) and dried. Finally, an 
HE4 nanobiosensor was formed.
Detection of HE4 by LSPR and ELISA
In the detection stage, the different concentrations of standard 
HE4 (1 pM to 0.1 µM) and the patient samples were incubated 
on the functionalized LSPR chip for 40 minutes, followed 
by a thorough rinsing with phosphate-buffered solution 
containing 0.05% Tween-20 to dissociate the nonspecific 
binding. Quantitative determination was performed using 
the ELISA kit according to the manufacturer’s instructions. 
Each value was averaged from three parallel experiments. 
A statistical evaluation of the correlation of the LSPR 
and ELISA methods was performed and computed using 
a software program (Origin 8.0, OriginLab Corporation, 
Northampton, MA).
Results and discussion
LSPR response to immobilization process
The LSPR spectra of the nanobiosensor in each processing 
step are shown in Figure 3. Before modification, the LSPR 
λmax of the bare silver nanochip was measured at 592.58 nm 
(Figure 3A). A representative LSPR λmax of the silver 
nanochip after modification with 11-mercaptoundecanoic 
acid was 619.85 nm with a corresponding LSPR ∆λmax of 
+27.27 nm (Figure 3B). After anti-HE4 immobilization, 
the LSPR λmax shifted to 630.97 nm, with an additional 
11.12 nm red shift (Figure 3C). After incubation in 500 pM 
HE4, the LSPR wavelength shifted to +14.48 nm, showing 
a λmax of 645.45 nm (Figure 3D). This experimental 
evidence clearly showed that HE4 in the buffer solution 
was detected successfully by the LSPR biosensor. The 
optical characteristics of the nanosensor are notably based 
on the wavelength shift of the absorbance peak, ∆λmax. 
Collimating lens
Fiber
Light source
Sensing nanochip
Focus lens
Spectrometer
PC-data processing
Fiber
Sample room
Figure 1 Schematic presentation of localized surface plasmon resonance experimental setup.
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Figure 2 Design of the localized surface plasmon resonance biosensor for HE4 detection using a direct assay format. (A) Glass substrate, (B) silver nanoparticles 
synthesized through NSL technology, (C) A self-assembled monolayer layer formed by incubation in 1 mM 11-mercaptoundecanoic acid, (D) incubation in 75 mM 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride/15 mM N-hydroxysuccinimide, (E) anti-HE4 antibody (10 µg/mL) covalently attached to the nanoparticles, and   
(F) different concentrations of the HE4 both in buffer and serum samples reacted with the anti-HE4. 
Abbreviation: HE4, human epididymis secretory protein 4.
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Figure 3 Localized surface plasmon resonance spectra for each step of the detection of 500 pM human epididymis secretory protein 4. (A) Bare silver nanochip, 
λmax = 592.58 nm, (B) 1 mM 11-mercaptoundecanoic acid, λmax = 619.85 nm, (C) functionalized biosensor with 10 µg/mL antibody, λmax = 630.97 nm, and (D) 500 pM HE4, 
λmax = 645.45 nm. 
Note: All spectra were collected at room temperature in air. 
Abbreviation: HE4, human epididymis secretory protein 4.
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According to Mie theory, the peak LSPR position is related 
to the refractive index around the particle. Therefore, the 
change in the local refractive index that accompanies the 
molecular binding can be sensed by the nanoparticles, and 
the quantitative detection of targets can be achieved by 
monitoring the ∆λmax when the analytes are bound to the 
nanoparticles.10
Calibration curve
Figure 4 shows a calibration curve of the nanosensor 
constructed by measuring the LSPR wavelength shifts 
after exposure of the anti-HE4 attachment surface to the 
HE4 standard solutions of concentrations ranging from 1 pM 
to 0.1 µM under optimal conditions. As seen from the data, 
the LSPR λmax values increased stepwise with increasing 
HE4 concentrations. Like many immunoassays, the curve 
is sigmoid rather than linear.25 In addition, a good linear 
relationship between the LSPR shifts and the logarithm of 
the HE4 concentration could be fitted to the experimental 
points from 10 pM to 10,000 pM (inset of Figure 4). The 
linear regression equation was LSPR (nm) = 3.72 × log [HE4] 
(M) + 47.37, with a linear correlation coefficient (R) of 0.997. 
This linear range is broader than that of the commercial HE4 
ELISA kit (15 pM to 900 pM), indicating that it is capable 
of testing the samples without predilution which could not 
be confirmed through a routine ELISA. Given that the noise 
level is defined as the standard deviation of the blank (n = 12), 
the limit of detection, defined as the analyte concentration 
corresponding to a signal-to-noise ratio of three (about 5 nm), 
was estimated to be 4 pM. This limit of detection was more 
than sufficient for analysis of HE4 in serum where normal 
values of HE4 are considered to be less than 150 pM.26 This 
detection limit is a little better than that obtained using the 
ELISA method for HE4 (15 pM). Therefore, the LSPR 
biosensor had good analytical performance for the detection 
of HE4, and was comparable with ELISA.
Selectivity, precision, regeneration,  
and stability tests
Several control experiments were designed to ensure that 
the results of Figure 4 were not disturbed by nonspecific 
adsorption. All the experiments were implemented in 
triplicate. Squamous cell carcinoma (SCC) antigen, 
another tumor marker and bovine serum albumin, the most 
abundant protein component in blood serum were chosen as 
interferences. The functionalized biosensor was incubated 
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Figure 4 A semilogarithmic curve of localized surface plasmon resonance shift versus the logarithm of HE4 concentration. 
Note: The inset shows the linear relationship between the localized surface plasmon resonance shift and the logarithm of HE4 concentration in the concentration range 
from 10 pM to 10000 pM. 
Abbreviations: HE4, human epididymis secretory protein 4; LSPR, localized surface plasmon resonance.
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Table 1 Precision tests of LSPR biosensor for HE4
HE4 concentration 
(pM)
Intrarun  
(n = 5, nm)
CV (%) Interrun  
(n = 5, nm)
CV (%)
500 12.16 ± 1.13 9.29 12.63 ± 0.90 7.13
5000 15.61 ± 1.11 7.11 16.18 ± 1.16 7.17
Abbreviations: LSPR, localized surface plasmon resonance; HE4, human epididymis 
secretory protein 4; CV, coefficient of variation.
Table 2 Regeneration and reusability of the LSPR biosensor
Biosensor  
code
LSPR shift (nm) Mean  
(nm)
SD CV (%)
1a 13.86 12.44 14.44 10.23 12.74 1.87 14.70
2b 13.54 12.52 12.86 11.49 12.60 0.85 8.24
Notes: Each LSPR shift obtained corresponds to a measurement cycle when the 
tested biosensor was freshly regenerated followed by the LSPR shift measurement 
procedures.  Concentration  of  HE4  was  500  pM.  aMeasurement  with  a  freshly 
prepared  anti-HE4-modified  biosensor;  bmeasurement  with  the  same  anti-HE4-
modified biosensor through 4 weeks of use. 
Abbreviations: LSPR, localized surface plasmon resonance; SD, standard deviation; 
CV, coefficient of variation.
with a solution of 500 pM SCC or bovine serum albumin. 
The same concentration of HE4 was also introduced to 
the nanosensor surface in the absence of anti-HE4. After 
phosphate-buffered solution washing, the LSPR shift value 
was measured. No discernible LSPR shift was observed. 
Thus, the nonspecific binding of protein molecules on the 
self-assembled monolayer-covered nanosensor was found 
to be relatively low. The results indicated that the selectivity 
of the LSPR biosensor based on the highly specific antigen-
antibody reaction and surface passivation with ethanolamine 
was excellent.
The precision within and between batches is an important 
factor in the practical application of the biosensor.25 The 
intrarun precision was tested at two HE4 concentration levels 
(500 pM and 5000 pM) using the LSPR biosensors of the 
same batch for five continuous measurements within one 
day. The interrun precision was tested similarly with five 
biosensors, which were selected randomly from five batches. 
The results in Table 1 suggest that the nanobiosensor showed 
acceptable precision and reproducibility.
Following completion of the antigen-antibody reaction, 
the nanochips were regenerated via exposure to 8 M 
urea solution, and then washed with ultrapure water. The 
reproducibility of responses from the identical biosensor and 
from different biosensors was evaluated by measuring 500 pM 
standard HE4 solution, and the coefficient of variation for the 
LSPR shift was obtained. After performing the corresponding 
HE4 incubation with the freshly regenerated biosensor four 
times, a coefficient of variation of 14.7% was obtained, as 
shown in Table 2. This value indicates that the anti-HE4-
modified sensor can provide reliable detection of HE4. The 
biosensor stored in the refrigerator at 4°C was regenerated 
and observed every week for one month. After one, 2, 3, and 
4 weeks, the extent of response for 500 pM HE4 dropped by 
2.30%, 7.21%, 9.66%, and 17.09%, respectively, compared 
with the initial signal. This drop in response seems to be 
related to gradual deactivation of the anti-HE4 antibody. The 
LSPR biosensor retained 80% of its initial responsiveness 
after regeneration seven times. The silver surface is 
susceptible to oxidative damage, which could directly affect 
the stability of the LSPR sensor. However, the nanochips 
were stable in air after chemical modification through to 
the end of the 4-week study. These results indicate good 
reusability and stability for the LSPR biosensor.
Comparison of results from the LSPR 
system and ELISA
This study investigated the availability of a domestic system 
for detecting HE4 in serum. A series of ten human serum 
samples, five from the ovarian cancer group and five from 
the control group, were screened for serum HE4 levels 
using the proposed LSPR sensor and an ELISA kit. According 
to the literature, the cutoff value for HE4 with 98% specificity 
is 150 pM.26 Therefore, a sample was defined positive when its 
concentration was more than 150 pM. The five ovarian cancer 
samples with red shifts ranging from 11 nm to 17 nm were 
shown to be positive. Meanwhile, red shifts less than 10.5 nm 
were observed in the negative controls. Thus, consistent 
results were achieved between the LSPR and ELISA meth-
ods in terms of semiquantitative analysis. Based on a t-test, 
differences in HE4 levels between the ovarian cancer group 
and the control group detected were statistically significant 
(P , 0.05) using both LSPR and ELISA. Furthermore, the 
LSPR sensor could specifically distinguish between ovarian 
cancer and the negative controls without the need for label-
ing in response to HE4 binding in the sera tested. The LSPR 
biosensor clearly has good specificity that cannot be disrupted 
by other proteins or components in serum.
The concentration of the ten samples was found to be 
within the range of 11.39–911.16 pM, which was also 
within the linear range of the LSPR sensor. A comparison 
between the two methods of analysis was also done using the 
regression line method.27 The results are shown in Figure 5. 
The analytical curve was calibrated using the correlation 
equation, ie, y = 83.88x − 677.07, with a correlation 
coefficient of 0.926. The results indicate that the LSPR 
biosensor could serve as a good alternative to the laborious 
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and time-consuming ELISA method for direct detection of 
HE4. Moreover, the technological barrier regarding transfer 
of bench research to clinical application was overcome to a 
certain extent. In terms of product commercialization, serum 
HE4 can be detected in real time using an antibody-coated 
LSPR sensor within 40 minutes without predilution, thereby 
reducing the chance of potential procedural errors.
Conclusion
Ideal biosensors should be rapid, sensitive, specific, label-free, 
stable, reproducible, cheap, portable, and easy to   operate.28 
The LSPR technique has many of these characteristics, 
making this method comparable with other immunoassay 
techniques. The LSPR biosensor has significant advantages 
in terms of label-free biomarker detection, a rapid test time, 
and in a direct assay format unlike the traditional immunoas-
say approaches, such as ELISA. Compared with chemilumi-
nescence analysis and current commercial surface plasmon 
resonance sensors, the LSPR sensor has outstanding features, 
including miniaturization, portability, and low cost.
A custom-built LSPR system was used for the first 
time in medical diagnostics in the field of gynecological 
  oncology. The experiments described in this study demon-
strate that a label-free LSPR technique could serve as a very 
effective alternative to the label-based conventional ELISA 
method. Furthermore, direct detection of protein targets in 
human serum, which retains the native specific properties 
of antibodies or proteins without complicated procedures, 
makes the LSPR method a very attractive strategy for cancer 
biomarker studies. Future studies need to be performed to 
construct a serum calibration curve. A large, randomized, 
case-controlled clinical study can be used to evaluate the 
applicability of this biosensor in medical diagnostics for 
tumors such as ovarian cancer. The LSPR biosensor is 
anticipated to be a promising platform for point-of-service 
medical diagnostics and should rival the commercially 
available instruments.
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